You are here: Industry Insights > CABP

News List

Paratek Announces FDA Approval of NUZYRA® for Treatment of Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
June 04, 2021
Paratek Pharmaceuticals Inc. announced that the U.S. FDA has approved the Company’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP).
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP) prnasia
May 26, 2021
Sinovant Sciences today announced positive topline results from Sinovant's Phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia (CABP).
XENLETA Demonstrates High Efficacy in Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
October 16, 2020
Nabriva Therapeutics announced in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 trials by age, XENLETA™ (lefamulin) demonstrated consistently high efficacy and similar safety and tolerability profiles across all ...
EU accepts marketing application for Paratek’s antibiotic pharmatimes
October 11, 2018
European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.